PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
The aim of this study is to evaluate the safety of prasugrel monotherapy without aspirin versus 12-month dual antiplatelet therapy (DAPT) in patients with STEMI using platinum-chrome everolimus-eluting stent (PtCr-EES: SYNERGYTM).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Patients scheduled for primary PCI with everolimus-eluting stent (PtCr-EES, SYNERGYTM)
• STEMI patients
• Patients who can continue dual antiplatelet therapy with aspirin and a P2Y12 inhibitor for 12 months
Locations
Other Locations
Japan
Kindai University Faculty of Medicine
RECRUITING
Sayama
Contact Information
Primary
Kuniaki Takahashi, MD, PhD
kuniaki.t.0125@gmail.com
+81-72-366-0221
Time Frame
Start Date: 2023-02-28
Estimated Completion Date: 2028-01-04
Participants
Target number of participants: 2258
Treatments
Active_comparator: No aspirin (Prasugrel monotherapy)
To start prasugrel monotherapy before primary percutaneous coronary intervention (PCI).
Active_comparator: 12-month DAPT
To start dual antiplatelet therapy with prasugrel and aspirin for 12 months before primary percutaneous coronary intervention (PCI).
Related Therapeutic Areas
Sponsors
Collaborators: Boston Scientific Corporation
Leads: Kindai University